In this episode of Beyond Longevity, Daphna speaks with Dr Peter Scriven, Co-Founder and Clinical & Scientific Director of LONGEVITY, about what longevity medicine should actually look like: moving from reactive, disease-led healthcare towards preventative, personalised medicine that tracks biomarkers, cardiovascular risk and health trajectory over time.

Dr Peter describes much of conventional healthcare as ‘failure-based medicine’ — a system designed to respond once something has gone wrong. He questions the reliance on population-based ‘normal’ laboratory ranges, which can obscure meaningful changes within an individual, and makes the case for longitudinal ‘human telemetry’: following biomarkers and other health data over time rather than relying on isolated snapshots.

They discuss what responsible longevity testing should look like, including a core panel of around 50–80 blood biomarkers, more targeted diagnostics according to age, sex, symptoms and individual goals, and the importance of having a clear clinical reason for every test. Dr Peter also explains why more testing is not necessarily better, and why interpretation, clinical oversight and sensible testing intervals matter.

The conversation examines the realities of longevity medicine and preventative health screening, from several hundred pounds for more focused assessments to several thousand when extensive diagnostics and medical imaging are included, and where he believes people should prioritise their spending.

Dr Peter explains how his father’s missed cardiovascular risk and inadequate lipid testing helped shape his approach to preventative medicine. He also discusses the largely unregulated ‘Wild West’ of longevity, including peptides and other interventions promoted ahead of strong clinical evidence, and the checks patients can make when assessing a longevity clinic or practitioner.

And beneath the diagnostics, biological-age testing and emerging technologies, he returns to the foundations of healthspan: movement, nutrition, sleep and purpose.

For those working with a limited budget, he identifies three areas he believes are worth considering first: a proper cardiovascular risk assessment, omega-3 to omega-6 balance, and GlycanAge testing.

https://longevityclinics.life/

https://www.linkedin.com/in/drpscriven/

00:00 Why Prevention Matters

03:12 Failure-Based Medicine

04:34 Human Telemetry Monitoring

06:28 Testing Without Overtesting

09:53 Core vs Targeted Panels

13:13 Cost and ROI of Diagnostics

17:54 Healthspan Intervention Pyramid

20:53 Normal Ranges vs Trajectories

24:36 Missed Risks Real Stories

28:46 Breaking Medical Silos

33:49 Renaissance Medic Mindset

36:05 Training Beyond Silos

36:49 Regulating Longevity Medicine

37:43 Patients or Permanent Clients

41:01 Too Much Testing Ethics

44:08 Peptides and Amateur Hype

45:42 How to Vet a Clinic

49:01 Budget Biomarkers That Matter

52:13 Foundations and Wearables

55:19 Future of Cellular Medicine

58:30 Long-Term Clinic Journey

01:00:00 Rapid Fire and Wrap Up